iotaSciences

Executive Summary

iotaSciences is a UK-based biotechnology company specializing in automation solutions for gentle single-cell isolation and cloning, with a focus on human induced pluripotent stem cells (iPSCs). Founded in 2018 in Cambridge, the company addresses a critical bottleneck in cell therapy and regenerative medicine: the need for efficient, high-throughput single-cell workflows that maintain cell viability and genomic integrity. Its modular systems enable researchers to accelerate cell-line engineering and clone selection, reducing manual labor and variability. The global cell therapy market is projected to exceed $50 billion by 2030, driving demand for tools that streamline production and quality control. iotaSciences positions itself as an enabler of next-generation therapies by improving the speed and reliability of cell-based research.

Upcoming Catalysts (preview)

• Q3 2026Launch of Next-Generation Single-Cell Cloning Platform80% success
• Q4 2026Strategic Partnership with a Major Cell Therapy Developer or CRO60% success
• Q1 2027Series A or B Funding Round to Scale Commercial Operations75% success